Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in Moderate to Severe Psoriasis
NCT05858645Phase 4Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Oct 2023
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of deucravacitinib in Psoriasis vulgaris (PV), sponsored by University of California, San Francisco. Started Oct 2023; status: recruiting.
02
Drugs
deucravacitinib
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT05858645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05858645.